Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo offers hope for older AML patients

NCT ID NCT02993523

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitidine. The goal was to see if the combination improves overall survival and remission rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

443 people

The number who actually took part.

Started

Feb 2017

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities. * Participant must be \>= 18 years of age. * Participant must have a projected life expectancy of at least 12 weeks. * Participant must be considered ineligible for induction therapy defined by the following: a. \>= 75 years of age; or b. \>= 18 to 74 years of age with at least one of the following comorbidities: i. Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction \<= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \<= 65% or Forced Expiratory Volume in 1 second (FEV1) \<= 65%; iv. Creatinine clearance \>= 30 mL/min to \< 45 ml/min; v. Moderate hepatic impairment with total bilirubin \> 1.5 to \<= 3.0 × Upper Limit of Normal (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment. * Participant must have an ECOG Performance status: 1. 0 to 2 for Participants \>= 75 years of age or 2. 0 to 3 for Participants \>= 18 to 74 years of age. * Participant must have adequate renal function as demonstrated by a creatinine \>= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection. * Participant must have adequate liver function as demonstrated by: 1. aspartate aminotransferase (AST) \<= 3.0 x ULN\* 2. alanine aminotransferase (ALT) \<= 3.0 x ULN\* 3. bilirubin \<= 1.5 x ULN\* \* Unless considered to be due to leukemic organ involvement i. Participants who are \< 75 years of age may have a bilirubin of \<= 3.0 x ULN * Female participants must be either postmenopausal defined as: 1. Age \> 55 years with no menses for 12 or more months without an alternative medical cause. 2. Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an follicle stimulating hormone (FSH) level \>40 international units per liter (IU/L); or 3. Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); or 4. Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control, starting at Study Day 1 through at least 90 days after the last dose of study drug. * Male participants who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug. * Female participants of childbearing potential must have negative results for pregnancy test performed: 1. At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and 2. Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been \> 7 days since obtaining the serum pregnancy test results. * Participant must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: * Participant has received treatment with the following: 1. A hypomethylating agent, venetoclax and/or chemo therapeutic agent for Myelodysplastic syndrome (MDS). 2. Chimeric Antigen Receptor (CAR)-T cell therapy. 3. Experimental therapies for MDS or Acute Myeloid Leukemia (AML). 4. Current participation in another research or observational study. * Participant has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation. * Participant has the following: a. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia. * Participant has acute promyelocytic leukemia * Participant has known active central nervous system (CNS) involvement with AML. * Participant has known human immunodeficiency virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards. * Participant is known to be positive for hepatitis B or C infection \[HCV Ab indicative of a previous or current infection; and/or positive HBs Ag or detected sensitivity on hepatitis B virus (HBV) deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) test for HBc Ab and/or HBs Ab positivity\] with the exception of those with an undetectable viral load within 3 months screening. Hepatitis B or C testing is not required. * Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment; additional details as described in the protocol. * Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment. * Participant has a cardiovascular disability status of New York Heart Association Class \> 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. * Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of azacitidine that in the opinion of the investigator would adversely affect his/her participating in this study. * Participant has a malabsorption syndrome or other condition that precludes enteral route of administration. * Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal). * Participant has a history of other malignancies within 2 years prior to study entry, with the exception of: 1. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; 2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; 3. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; requires discussion with TA MD. * Participant has a white blood cell count \> 25 × 10\^9/L. (Hydroxyurea or leukapheresis are permitted to meet this criterion.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia (AML)

Contacts and locations

Locations

  • AP-HP - Hopital Saint-Louis /ID# 153787

    Paris, 75010, France

  • AZ Sint-Jan Brugge /ID# 154041

    Bruges, 8000, Belgium

  • Aalborg University Hospital /ID# 154047

    Aalborg, North Denmark, 9000, Denmark

  • Aichi Cancer Center Hospital /ID# 200824

    Nagoya, Aichi-ken, 464-8681, Japan

  • Akademiska Sjukhuset /ID# 153034

    Uppsala, Uppsala County, 751 85, Sweden

  • Akershus universitetssykehus /ID# 154279

    Nordlenangen, Akershus, 1474, Norway

  • Albert Alberts Stem Cell Transplant Centre /ID# 153684

    Pretoria, Gauteng, 0044, South Africa

  • Alfred Health /ID# 154275

    Melbourne, Victoria, 3004, Australia

  • Ankara Universitesi Fakultesi /ID# 155200

    Ankara, 06620, Turkey (Türkiye)

  • Assaf Harofeh Medical Center /ID# 158063

    Be’er Ya‘aqov, 70300, Israel

  • Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 152879

    Naples, 80131, Italy

  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 171220

    Ancona, 60126, Italy

  • Azienda Ospedaliero-Universitaria Sant'Andrea /ID# 152876

    Rome, 00189, Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni /ID# 152875

    Bergamo, 24127, Italy

  • Baylor Scott & White Medical Center- Temple /ID# 157191

    Temple, Texas, 76508-0001, United States

  • Beth Israel Deaconess Medical Center /ID# 201155

    Boston, Massachusetts, 02215-5400, United States

  • CHU Bordeaux - Hopital Haut Leveque /ID# 153789

    Pessac, Gironde, 33604, France

  • Changhua Christian Hospital /ID# 153899

    Changhua, Changhua County, 50006, Taiwan

  • China Medical University Hospital /ID# 153904

    Taichung, 40447, Taiwan

  • Chu Angers /Id# 153792

    Angers, 49933, France

  • City of Hope /ID# 154105

    Duarte, California, 91010, United States

  • Clinical Hospital Dubrava /ID# 153515

    Zagreb, City of Zagreb, 10000, Croatia

  • Columbia Univ Medical Center /ID# 154101

    New York, New York, 10032-3725, United States

  • Cotton-O'Neil Clinical Res Ctr /ID# 155136

    Topeka, Kansas, 66606, United States

  • Dana-Farber Cancer Institute /ID# 167009

    Boston, Massachusetts, 02215, United States

  • Debreceni Egyetem Klinikai Kozpont /ID# 153814

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 158990

    Budapest, 1097, Hungary

  • Drammen Sykehus /ID# 154280

    Drammen, Buskerud, 3004, Norway

  • Duke Cancer Center /ID# 154106

    Durham, North Carolina, 27710-3000, United States

  • Dup_VO Hematologi /ID# 153174

    Lund, 221 85, Sweden

  • Duplicate_Hospital de Braga /ID# 154797

    Braga, 4710-423, Portugal

  • Duplicate_Kindai University Hospital /ID# 167662

    Osaka-sayama-shi, Osaka, 589-8511, Japan

  • Duplicate_Klinicki bolnicki centar Osijek /ID# 153623

    Osijek, County of Osijek-Baranja, 31000, Croatia

  • Duplicate_Konkuk University Medical Ctr /ID# 153973

    Seoul, Seoul Teugbyeolsi, 05030, South Korea

  • Duplicate_Kyoto Prefectural University of Medicine /ID# 167661

    Kyoto, Kyoto, 602-8566, Japan

  • Duplicate_Landeskrankenhaus Salzburg /ID# 169719

    Salzburg, 5020, Austria

  • Duplicate_Regional Oncology Dispensary /ID# 153264

    Penza, Penza Oblast, 440071, Russia

  • Duplicate_Semmelweis Egyetem /ID# 153815

    Budapest, 1088, Hungary

  • EMMC Cancer Care /ID# 154991

    Brewer, Maine, 04412, United States

  • Emory Midtown Infectious Disease Clinic /ID# 162534

    Atlanta, Georgia, 30322, United States

  • Fakultni Nemocnice Brno /ID# 154019

    Brno, 625 00, Czechia

  • Fakultni nemocnice Hradec Kralove /ID# 154021

    Hradec Králové, 500 05, Czechia

  • Fakultni nemocnice Ostrava /ID# 154017

    Ostrava, 708 52, Czechia

  • Fakultni nemocnice Plzen /ID# 154018

    Pilsen, 305 99, Czechia

  • Federal State Budgetary Ins NRC for Hematology of MoH of Russian Federation /ID# 155740

    Moscow, 125167, Russia

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 152882

    Milan, 20122, Italy

  • Fondazione PTV Policlinico Tor Vergata /ID# 152881

    Rome, Roma, 00133, Italy

  • Fort Wayne Medical Oncology /ID# 157190

    Fort Wayne, Indiana, 46804, United States

  • Fujian Medical University Union Hospital /ID# 167314

    Fuzhou, Fujian, 350001, China

  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli /ID# 152877

    Reggio Calabria, 89124, Italy

  • Gunmaken Saiseikai Maebashi Hospital /ID# 168316

    Maebashi, Gunma, 371-0821, Japan

  • Hacettepe University Faculty of Medicine /ID# 202073

    Ankara, 06100, Turkey (Türkiye)

  • Hadassah /ID# 154172

    Jerusalem, 91120, Israel

  • Hanusch Krankenhaus /ID# 155676

    Vienna, 1140, Austria

  • Haukeland University Hospital /ID# 154281

    Bergen, Hordaland, 5021, Norway

  • Helsinki University Hospital /ID# 155223

    Helsinki, Uusimaa, 00290, Finland

  • Henan Cancer Hospital /ID# 167320

    Zhengzhou, Henan, 450008, China

  • Hitachi General Hospital /ID# 201109

    Hitachi-shi, Ibaraki, 317-0077, Japan

  • Hospital Clinic de Barcelona /ID# 153255

    Barcelona, 08036, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 153260

    Madrid, 28007, Spain

  • Hospital Santa Creu i Sant Pau /ID# 153193

    Barcelona, 08041, Spain

  • Hospital Universitario 12 de Octubre /ID# 153258

    Madrid, 28041, Spain

  • Hospital Universitario Virgen de la Victoria /ID# 153257

    Málaga, 29010, Spain

  • Hospital Universitario de Navarra /ID# 153254

    Pamplona, Navarre, 31008, Spain

  • Hospital Universitario de la Princesa /ID# 153256

    Madrid, 28006, Spain

  • Hospital Universitario y Politecnico La Fe /ID# 153259

    Valencia, 46026, Spain

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 153099

    Ribeirão Preto, São Paulo, 14051-140, Brazil

  • Hospital de Clinicas de Porto Alegre /ID# 157779

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • IPO Porto FG, EPE /ID# 154138

    Porto, 4200-072, Portugal

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 152883

    Bologna, 40138, Italy

  • IUCT Oncopole /ID# 153788

    Toulouse, 31059, France

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 167487

    Tianjin, Tianjin Municipality, 300020, China

  • Instituto de Ensino e Pesquisa São Lucas /ID# 157778

    São Paulo, São Paulo, 01236-030, Brazil

  • Instituto do Câncer do Estado de São Paulo - ICESP /ID# 153095

    São Paulo, São Paulo, 01246-000, Brazil

  • Jiangsu Province Hospital /ID# 167489

    Nanjing, Jiangsu, 210029, China

  • Johns Hopkins University /ID# 154104

    Baltimore, Maryland, 21287, United States

  • Juntendo University Hospital /ID# 168309

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Juravinski Cancer Centre /ID# 153650

    Hamilton, Ontario, L8V 1C3, Canada

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 153902

    Kaohsiung City, 807, Taiwan

  • Karolinska University Hospital /ID# 170003

    Stockholm, 171 76, Sweden

  • Klinicki bolnicki centar Zagreb /ID# 153383

    Zagreb, City of Zagreb, 10000, Croatia

  • Kuzbass Regional Clinical Hospital /ID# 157461

    Kemerovo, Kemerovo Oblast, 650099, Russia

  • Kyiv Regional Onco Dispensary /ID# 153514

    Kyiv, 04107, Ukraine

  • Kyiv city clinical hospital #9 /ID# 153510

    Kiev, Vinnytsia Oblast, 04112, Ukraine

  • Kyushu University Hospital /ID# 169095

    Fukuoka, Fukuoka, 812-8582, Japan

  • Massachusetts General Hospital /ID# 200752

    Boston, Massachusetts, 02114, United States

  • Medizinische Hochschule Hannover /ID# 153055

    Hanover, 30625, Germany

  • Medizinische Universitaet Graz /ID# 157882

    Graz, Styria, 8036, Austria

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 165077

    New York, New York, 10065-6007, United States

  • Moscow State budget healthcare /ID# 155738

    Moscow, Moscow, 125284, Russia

  • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council /ID# 153511

    Dnipro, 49102, Ukraine

  • NTT Medical Center Tokyo /ID# 167975

    Shinagawa-ku, Tokyo, 141-8625, Japan

  • Nagasaki University Hospital /ID# 168632

    Nagasaki, Nagasaki, 852-8501, Japan

  • Nanfang Hospital of Southern Medical University /ID# 170148

    Guangzhou, Guangdong, 510515, China

  • National Hospital Organization Kyushu Cancer Center /ID# 201111

    Fukuoka, Fukuoka, 811-1395, Japan

  • National Hospital Organization Mito Medical Center /ID# 168219

    Higashi, Ibaraki, 311-3193, Japan

  • National Taiwan University Hospital /ID# 153900

    Taipei, 100, Taiwan

  • Nizhny Novgorod Regional Clinical Hospital named N.A. Semashko /ID# 153268

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603126, Russia

  • Northwestern University Feinberg School of Medicine /ID# 201133

    Chicago, Illinois, 60611-2927, United States

  • Norton Cancer Institute /ID# 154992

    Louisville, Kentucky, 40202-3700, United States

  • Okayama University Hospital /ID# 204124

    Okayama, Okayama-ken, 700-8558, Japan

  • Ondokuz Mayis Universitesi Tip /ID# 155201

    Samsun, 55139, Turkey (Türkiye)

  • Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 154888

    Linz, Upper Austria, 4010, Austria

  • Ordensklinikum Linz GmbH Elisabethinen /ID# 154885

    Linz, Upper Austria, 4010, Austria

  • Osaka Metropolitan University Hospital /ID# 169055

    Osaka, Osaka, 545-8586, Japan

  • Ospedale Policlinico San Martino /ID# 158104

    Genova, 16132, Italy

  • Osrodek Badan Klinicznych przy Szpitalu Specjalistycznym im. Ludwika Rydygiera w /ID# 169846

    Krakow, Lesser Poland Voivodeship, 31-826, Poland

  • Ottawa Hospital Research Institute /ID# 153541

    Ottawa, Ontario, K1H 8L6, Canada

  • Poltava Reg Clin Hosp Sklifoso /ID# 153513

    Poltava, 36011, Ukraine

  • Presidio Ospedaliero Vito Fazzi /ID# 170837

    Lecce, Apulia, 73100, Italy

  • Princess Alexandra Hospital /ID# 154272

    Woolloongabba, Queensland, 4102, Australia

  • Princess Margaret Cancer Centre /ID# 153651

    Toronto, Ontario, M5G 2M9, Canada

  • Qilu Hospital of Shandong University /ID# 167485

    Jinan, 250012, China

  • Rabin Medical Center /ID# 154176

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus /ID# 154174

    Haifa, 3109601, Israel

  • Royal Adelaide Hospital /ID# 154271

    Adelaide, South Australia, 5000, Australia

  • Royal Perth Hospital /ID# 154274

    Perth, Western Australia, 6000, Australia

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 167318

    Shanghai, Shanghai Municipality, 200065, China

  • SP ZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 153385

    Chorzów, Silesian Voivodeship, 41-500, Poland

  • Saitama Medical University International Medical Center /ID# 167814

    Hidaka-shi, Saitama, 350-1298, Japan

  • Samara State Medical University /ID# 157462

    Samara, 443099, Russia

  • Samsung Medical Center /ID# 153674

    Seoul, 06351, South Korea

  • Saratov State Medical University n.a. V.I. Razumovskiy /ID# 153267

    Saratov, Saratov Oblast, 410012, Russia

  • Semmelweis Egyetem /ID# 153816

    Budapest, 1085, Hungary

  • Seoul National University Hospital /ID# 153675

    Seoul, 03080, South Korea

  • Sepctrum Health Medical Center /ID# 159522

    Grand Rapids, Michigan, 49503, United States

  • Sir Charles Gairdner Hospital /ID# 163924

    Nedlands, Western Australia, 6009, Australia

  • Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 153813

    Kaposvár, Somogy County, 7400, Hungary

  • St Vincent's Hospital Melbourne /ID# 155094

    Melbourne, Victoria, 3065, Australia

  • St. Paul's Hospital /ID# 159644

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 157460

    Ryazan, Ryazan Oblast, 390039, Russia

  • Sykehuset Ostfold Kalnes /ID# 157755

    Grålum, 1714, Norway

  • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz Josa Andras Okta /ID# 169854

    Nyíregyháza, Nyiregyhaza, 4400, Hungary

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 153812

    Szeged, Csongrád megye, 6725, Hungary

  • Tampere University Hospital /ID# 154963

    Tampere, Pirkanmaa, 33520, Finland

  • Tel Aviv Sourasky Medical Center /ID# 154175

    Tel Aviv, Tel Aviv, 6423906, Israel

  • Tennessee Oncology-Nashville Centennial /ID# 200854

    Nashville, Tennessee, 37203-1632, United States

  • The Chaim Sheba Medical Center /ID# 154173

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 167317

    Hangzhou, Zhejiang, 310006, China

  • The First Hospital of Jilin University /ID# 167490

    Changchun, Jilin, 130021, China

  • The Jikei University Daisan Hospital /ID# 168745

    Komae-shi, Tokyo, 201-8601, Japan

  • The Royal Melbourne Hospital /ID# 155095

    Parkville, Victoria, 3050, Australia

  • The Second Hospital of Hebei Medical University /ID# 167316

    Shijiazhuang, Hebei, 050000, China

  • Tohoku University Hospital /ID# 169259

    Sendai, Miyagi, 9808574, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital /ID# 168639

    Bunkyo-ku, Tokyo, 113-8677, Japan

  • Tom Baker Cancer Centre /ID# 159645

    Calgary, Alberta, T2N 4N2, Canada

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 167315

    Wuhan, Hubei, 430022, China

  • Turku University Hospital /ID# 154964

    Turku, 20520, Finland

  • UCL Saint-Luc /ID# 153391

    Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium

  • UZ Brussel /ID# 153393

    Jette, Brussels Capital, 1090, Belgium

  • UZ Gent /ID# 153392

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Uddevalla sjukhus /ID# 156875

    Uddevalla, Västra Götaland County, 451 80, Sweden

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167493

    Wuhan, Hubei, 430022, China

  • Universitaetsklinikum Frankfurt /ID# 153060

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitaetsklinikum Halle (Saale) /ID# 153058

    Halle, 06120, Germany

  • Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 153056

    Hamburg, 20246, Germany

  • Universitaetsklinikum Muenster /ID# 153059

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitaetsklinikum St. Poelten /ID# 167436

    Sankt Pölten, Lower Austria, 3100, Austria

  • Universitaetsklinikum Ulm /ID# 153054

    Ulm, Baden-Wurttemberg, 89081, Germany

  • University Of Vermont Medical /ID# 157196

    Burlington, Vermont, 05405, United States

  • University of California, Davis Comprehensive Cancer Center /ID# 162725

    Sacramento, California, 95817, United States

  • University of California, Los Angeles /ID# 154107

    Los Angeles, California, 90095, United States

  • University of Chicago Medicine /ID# 154108

    Chicago, Illinois, 60637-1426, United States

  • University of Fukui Hospital /ID# 167432

    Yoshida-gun, Fukui, 910-1193, Japan

  • University of Pittsburgh MC /ID# 154102

    Pittsburgh, Pennsylvania, 15260, United States

  • University of Pretoria /ID# 153682

    Pretoria, Gauteng, 0001, South Africa

  • University of Texas MD Anderson Cancer Center /ID# 154100

    Houston, Texas, 77030, United States

  • University of Utah /ID# 157192

    Salt Lake City, Utah, 84112-5500, United States

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 153389

    Wroclaw, Lower Silesian Voivodeship, 50-556, Poland

  • VA Caribbean Healthcare System /ID# 160507

    San Juan, 00921-3201, Puerto Rico

  • West China Hospital, Sichuan University /ID# 167492

    Chengdu, Sichuan, 610041, China

  • Yamagata University Hospital /ID# 167634

    Yamagata, Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.